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Atrial Fibrillation at Baseline and During
Follow-Up in ALLHAT (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial)
L. Julian Haywood, MD,* Charles E. Ford, PHD,† Richard S. Crow, MD,‡
Barry R. Davis, MD, PHD,† Barry M. Massie, MD,§ Paula T. Einhorn, MD,
Angela Williard, RN, BSN,¶ for the ALLHAT Collaborative Research Group
Los Angeles and San Francisco, California; Houston, Texas; Minneapolis, Minnesota; Bethesda, Maryland;
and New Orleans, Louisiana
Objectives The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment
with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (chlorthalidone) in preventing coro-
nary heart disease (CHD) or other cardiovascular events. This subanalysis examines baseline prevalence and in-trial
incidence of new-onset atrial fibrillation (AF) or atrial flutter (AFL) and their influence on clinical outcomes.
Background Limited information is available on whether atrial fibrillation incidence is affected differentially by different
classes of antihypertensive medications or treatment with statins.
Methods AF/AFL was identified from baseline and follow-up electrocardiograms performed biannually. Analyses were per-
formed to identify characteristics associated with baseline AF/AFL and its subsequent incidence.
Results AF/AFL was present at baseline in 423 participants (1.1%), more frequent in men (odds ratio: 1.72; 95% confi-
dence interval [CI]: 1.37 to 2.17) and nonblacks (odds ratio: 2.09; 95% CI: 1.58 to 2.75). Its prevalence in-
creased with age (p  0.001) and was associated with CHD, cardiovascular disease, obesity, and high-density
lipoprotein cholesterol 35 mg/dl. New-onset AF/AFL was associated with the same baseline risk factors plus
electrocardiogram left ventricular hypertrophy. It occurred in 641 participants (2.0%) and, excluding doxazosin,
did not differ by antihypertensive treatment group or, in a subset of participants, by pravastatin versus usual
care. Baseline AF/AFL was associated with increased mortality (hazard ratio [HR]: 2.82; 95% CI: 2.36 to 3.37;
p  0.001), stroke (HR: 3.63; 95% CI: 2.72 to 4.86; p  0.001), heart failure (HR: 3.17; 95% CI: 2.38 to 4.25;
p  0.001), and fatal CHD or nonfatal myocardial infarction (HR: 1.64; 95% CI: 1.22 to 2.21; p  0.01). There
was a nearly 2.5-fold increase in mortality risk when AF/AFL was present at baseline or developed during the
trial (HR: 2.42; 95% CI: 2.11 to 2.77; p  0.001).
Conclusions In this high-risk hypertensive population, pre-existing and new-onset AF/AFL were associated with increased
mortality. Excluding doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus
usual care did not affect AF/AFL incidence. (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial [ALLHAT]; NCT00000542) (J Am Coll Cardiol 2009;54:2023–31) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.020v
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itrial fibrillation (AF) is the most common clinically
ignificant cardiac arrhythmia (1–3). It is associated with
arkedly increased risks of stroke, heart failure, and cardio-
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Atrial Fibrillation in the ALLHAT Study November 24, 2009:2023–31prevalence of AF increases with
age. Other risk factors for AF
include heart failure, diabetes,
left atrial enlargement, left ven-
tricular hypertrophy (LVH), and
specific triggers such as hyper-
thyroidism and excessive alcohol
use (3–6). Atrial flutter (AFL) is
known to have similar risk fac-
tors and outcomes.
In the Framingham Heart
Study, AF prevalence increased
from 0.5% of individuals age 50
to 59 years to 9% of those 80 to
89 years. Hypertension was asso-
ciated with a significant 1.8 odds
ratio (OR) for developing atrial
fibrillation (p  0.001) and a
population-attributable risk of
14% (6). At age 40 years or older,
lifetime risk for AF development
has been estimated at 25%, with
risk for men somewhat higher
than for women (7). Data from
the ATRIA (Anticoagulation
and Risk Factor in Atrial Fibril-
lation) study and the National
Center for Health Statistics sug-
est that the prevalence of AF may be lower in African
mericans despite the higher incidence of stroke and deaths
rom stroke in this group (8,9).
The ALLHAT (Antihypertensive and Lipid-Lowering
reatment to Prevent Heart Attack Trial), with 42,418
articipants, is the largest clinical trial in a hypertensive
opulation and thus offers an opportunity to investigate the
revalence of AF at baseline in a well-defined hypertensive
opulation and its new appearance during a prolonged
ollow-up experience (1994 to 2002) (10–14). The high
roportion of African Americans (36%) and type 2 diabetic
articipants (36%) and the older age of the participants
35% ages 70 years) allows assessment of the impact of
hese characteristics on AF occurrence.
Further, limited information is available on whether AF
ncidence is affected differentially by different classes of antihy-
ertensive medications or treatment with statins. Recent data
ave suggested that treatment with angiotensin-converting
nzyme (ACE) inhibitors and angiotensin receptor blockers
ARBs) may reduce the incidence or recurrence of AF in
atients with hypertension, heart failure, LVH on electro-
ardiogram (ECG), or prior episodes of AF (15–17).
LLHAT participants, randomized to 4 antihypertensive
reatment arms, allow comparison of the ability of an ACE
nhibitor (lisinopril), a dihydropyridine calcium-channel
locker (amlodipine), and an alpha-adrenoreceptor blocker
doxazosin) relative to a thiazide-like diuretic (chlorthali-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AF  atrial fibrillation
AFL  atrial flutter
ARB  angiotensin
receptor blocker
ASCVD  atherosclerotic
cardiovascular disease
BMI  body mass index
BP  blood pressure
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
ECG  electrocardiogram
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
LVH  left ventricular
hypertrophy
OR  odds ratio
PH  proportional hazardsone) to prevent incident AF. A subset of participants, 1andomized to pravastatin or usual care, allows comparison
f a statin’s ability to prevent incident AF relative to usual
are.
ethods
he rationale and design of the ALLHAT study have been
eported (10). Briefly, ALLHAT was a randomized, double-
lind, practice-based, multicenter clinical trial sponsored by the
ational Heart, Lung, and Blood Institute. It was designed to
etermine whether the calcium-channel blocker, the ACE
nhibitor, or the alpha-blocker was superior to the thiazide-like
iuretic in preventing coronary heart disease (CHD) or other
ardiovascular disease (CVD) events. A lipid-lowering trial
omponent involved a subset of participants, randomly as-
igned to open-label pravastatin or usual care (13). Participants
ere hypertensive men and women 55 years of age with at
east 1 additional CVD risk factor (10). Individuals with a
istory of hospitalized or treated symptomatic heart failure
nd/or known impaired left ventricular function (ejection
raction35%) were excluded. Individuals with AF/AFL were
ot excluded. Blood pressure (BP) eligibility was defined on
he basis of the participant’s current treatment status and
verage BP at 2 visits. For untreated participants, average
ystolic BP had to be in the range of 140 to 180 mm Hg and
iastolic, 90 to 100 mm Hg, at both visits. Treated participants
ad to be on 1 to 2 antihypertensive drugs and have BP
160/100 mm Hg at visit 1 and BP180/110 mm Hg at visit
. To maximize statistical power, 1.7 times as many partici-
ants were assigned to chlorthalidone than each alternative
reatment (18). Participants were recruited at 623 centers in the
.S., Canada, Puerto Rico, and the U.S. Virgin Islands,
etween February 1994 and January 1998 (19,20). All partic-
pants gave written informed consent, and all centers obtained
nstitutional review board approval.
Closeout for the nondoxazosin groups was October 2001 to
arch 2002 (12). The doxazosin arm was terminated in
ebruary 2000 (11), and its follow-up interval (average 3.2
ears) differed from the other treatment groups (average 4.9
ears). Separate follow-up analyses were done for the doxazosin
nd nondoxazosin comparisons with chlorthalidone (12,13).
The treatment goal was BP 140/90 mm Hg, achieved
y titration of the assigned study drug (step 1) and addition
f open-label agents when necessary. Nonpharmacological
pproaches to treatment of hypertension were recom-
ended according to national guidelines (21,22). Step 1
rug dosages were 12.5, 12.5 (sham titration), and 25
g/day for chlorthalidone; 2.5, 5, and 10 mg/day for
mlodipine; 10, 20, and 40 mg/day for lisinopril, and 2, 4,
nd 8 mg/day for doxazosin. Additional study-supplied,
pen-label drugs were also available for BP control, and
ther drugs, including low doses of open-label step 1 drug
lasses, were permitted if clearly indicated (10). After initial
itration visits, participants were seen every 3 months in yearand every 4 months thereafter.
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November 24, 2009:2023–31 Atrial Fibrillation in the ALLHAT StudyCG analysis. ECGs were recorded at clinical sites using
tandardized procedures at baseline and biannually and
orwarded to the ECG Reading Center (University of
innesota, Minneapolis) (23). Baseline and follow-up
CGs were coded for rhythm, with AF and AFL coded
eparately using Minnesota Code definitions. In this report,
F and AFL were considered together (AF/AFL).
tatistical methods. Prevalence rates for AF/AFL were
ased on baseline ECGs and were directly adjusted for
istributional differences in age, race, and sex using the
ombined ALLHAT population as the standard. Incidence
ates for new AF/AFL were based on follow-up ECGs
mong participants without AF/AFL at baseline. Preva-
ence and incidence of AF/AFL were tabulated for sub-
roups defined by demographic and clinical characteristics.
ultivariable logistic regression analyses were done to
xamine the relative odds of AF/AFL prevalence and
ncidence for the prognostic characteristics. Likewise, AF/
FL incidence by antihypertensive treatment group and for
revalence of AF/AFL per 1,000 Participants by Baseline CharacteTable 1 Prevalence of AF/AFL per 1,000 Participants by Basel
Baseline
Characteristic
Sample Size,
n (%)
Number W
AF/AFL
All 39,056 (100.0)‡ 423
Age 55–69 yrs 25,274 (64.7) 154
Age 70–79 yrs 11,275 (28.9) 188
Age 80 yrs 2,507 (6.4) 81
Women 17,914 (45.9) 136
Men 21,142 (54.1) 287
Black 13,485 (34.5) 80
Nonblack 25,571 (65.5) 343
Diabetic 13,868 (35.5) 132
Nondiabetic 25,188 (64.5) 291
Smoker 8,516 (21.8) 60
Nonsmoker 30,540 (78.2) 363
CHD absent 29,032 (74.3) 271
CHD present 10,024 (25.7) 152
LVH absent 34,442 (88.2) 360
LVH present 1,876 (4.8) 24
ASCVD absent 20,738 (53.1) 159
ASCVD present 18,318 (46.9) 264
No aspirin 24,778 (63.4) 279
Aspirin use 14,278 (36.6) 144
Not treated for hypertension 3,809 (9.8) 33
Treated for hypertension 35,247 (90.2) 390
BMI 30 kg/m2 22,641 (58.0) 245
BMI 30 kg/m2 16,299 (41.7) 175
eGFR 60 ml/min per 1.73 m2 31,165 (79.8) 319
eGFR 60 ml/min per 1.73 m2 6,730 (17.2) 95
HDL 35 mg/dl 30,408 (77.9) 293
HDL 35 mg/dl 7,320 (18.7) 118
Includes 20 participants with atrial flutter (AFL). †Direct adjusted for distributional differences i
ecorded and an additional 1,735 did not have a baseline electrocardiogram. The p value represe
AF  atrial fibrillation; ASCVD  atherosclerotic cardiovascular disease (history or documente
ectoris, intermittent claudication, transient ischemic attack; documented coronary, peripheral vas
ortic aneurysm detected by ultrasound, computed tomography, or X-ray; or carotid or femoral bruits); BM
25); HDL  high-density lipoprotein cholesterol; LVH  left ventricular hypertrophy (tall R-wave in presenravastatin versus usual care was compared in multiple
ogistic analyses, with and without adjustment for relevant
ovariates.
Cumulative 6-year event rates for CHD, death, stroke,
nd heart failure were calculated using the Kaplan-Meier
rocedure. Log-rank tests and Cox proportional hazards
PH) models incorporating the participant’s entire trial
xperience were used to evaluate differences between cumu-
ative event curves and to obtain 2-sided p values. Only the
H results are presented, because p values were essentially
dentical. Hazard ratios (HRs) and 95% confidence intervals
CIs) were obtained from the PH models (24). To assess
isk of death after the development of new AF/AFL or its
resence at baseline, a time-dependent PH model was used
ith a time-varying indicator variable for presence or
bsence of AF/AFL. In this latter analysis, participants
ithout AF/AFL at baseline remained in the AF/AFL
bsent risk group until new-onset AF/AFL was ascertained,
t which time they were reclassified as AF/AFL present,
sharacteristics
Prevalence
Crude Rate Adjusted Rate†
per 1,000 p Value per 1,000 p Value
10.8 — — —
6.1 0.001 6.1 0.001
16.7 16.2
32.3 35.1
7.6 0.001 7.5 0.001
13.6 13.8
5.9 0.001 6.4 0.001
13.4 12.9
9.5 0.06 10.3 0.51
11.6 11.1
7.0 0.001 8.9 0.20
11.9 11.3
9.3 0.001 10.1 0.04
15.2 13.2
10.5 0.33 10.3 0.27
12.8 13.6
7.7 0.001 9.2 0.003
14.4 12.7
11.3 0.28 12.5 0.001
10.1 8.7
8.7 0.17 8.7 0.14
11.1 11.1
10.8 0.94 9.5 0.001
10.7 12.7
10.2 0.005 10.9 0.52
14.1 11.0
9.6 0.001 10.0 0.002
16.1 14.3
race, and sex. ‡Of the 42,418 randomized participants, 1,627 had no study electrocardiograms
probability of type I error for the test of no difference between subgroup proportions.
nce of myocardial infarction or stroke older than 6 months, revascularization procedure, angina
r carotid stenosis of50%; documented ischemic heart disease; ankle-arm index0.9; abnormalristicine C
ith
*
n age,
nts the
d evide
cular, oI  body mass index; CHD  coronary heart disease; eGFR  estimated glomerular filtration rate
ce of ST-wave abnormalities or T-wave inversion on Minnesota-coded electrocardiogram).
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Atrial Fibrillation in the ALLHAT Study November 24, 2009:2023–31nd participants who died before a follow-up ECG could be
btained were classified as AF/AFL absent.
esults
revalence of AF/AFL. Baseline ECGs were available for
2.1% of the 42,418 randomized ALLHAT participants.
he proportion of participants missing a baseline ECG
7.8% chlorthalidone, 8.0% amlodipine, 8.2% lisinopril,
.8% doxazosin) did not differ by treatment group (p 
.770). However, the proportion without follow-up ECGs
23.3% chlorthalidone, 23.4% amlodipine, 26.0% lisinopril)
as higher in the lisinopril group (p  0.001). The
oxazosin group had the highest proportion missing
29.5%), likely due to the early rapid termination of this arm.
Pre-existing AF/AFL was present in 423 (1.1%) of the
9,056 participants evaluated. Of these, only 20 had AFL.
stimated ORs and Corresponding SEs and 95% CIsor Prevalence of AF/AFL at Baseline AmongLLHAT Participants
Table 2
E timated ORs and Corr ponding SEs and 95% CIs
for Prevalence of AF/AFL at Baseline Among
ALLHAT Participants
Baseline Characteristic* OR SE (OR) 95% CI p Value
Age, yrs 1.098 0.008 1.084–1.113 0.001
Sex, female/male 0.581 0.069 0.461–0.732 0.001
Race, black/nonblack 0.479 0.068 0.363–0.632 0.001
Diabetic 0.856 0.101 0.680–1.078 0.19
Smoker 0.807 0.129 0.590–1.103 0.18
With CHD 1.343 0.156 1.070–1.686 0.01
With LVH 1.298 0.286 0.843–1.999 0.24
Treated for hypertension 1.347 0.269 0.911–1.991 0.14
Aspirin user 0.632 0.073 0.503–0.793 0.001
BMI 30 kg/m2 1.407 0.157 1.130–1.752 0.002
eGFR 60 ml/min per 1.73 m2 0.871 0.112 0.676–1.121 0.28
HDL 35 mg/dl 1.412 0.173 1.111–1.796 0.005
stimates are based on a multiple logistic regression model (n  35,029). *ASCVD was excluded
rom model because CHD is a component.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
evelopment of AF/AFL During Follow-Up per 1,000 Participants bTable 3 Development of AF/AFL During Follow-Up per 1,000 Pa
Treatment Group
(Mean Follow-Up)
Sample
Size
New*
AF/AFL
Events
per 1,0
Full trial (4.9 yrs)
Chlorthalidone 11,695 244 20.9
Amlodipine 6,935 155 22.4
Lisinopril 6,702 138 20.6
Doxazosin-Chlorthalidone (3.2 yrs)
Chlorthalidone 11,695 142 12.1
Doxazosin 6,392 104 16.3
Lipid-lowering trial (4.8 yrs)
Usual care 4,255 82 19.4
Pravastatin 4,327 85 19.8
he occurrence of new AF/AFL could not be ascertained in 8,025 (24.1%) of the 33,357 nondoxaz
he 10,355 lipid-lowering trial participants. *There were 14 AF and 2 AFL cases among the 1,735
as negative for AF/AFL. The p value represents the probability of type I error for the 2-sided test
19.3/1,000) and pravastatin (19.6/1,000). ‡The variables listed in Table 5 were included in the multipl
OR  odds ratio; other abbreviations as in Table 1.he prevalence of AF/AFL was, respectively, 10.5, 11.9,
0.6, and 10.7 per 1,000 participants in the chlorthalidone,
isinopril, amlodipine, and doxazosin groups. These differ-
nces were not statistically significant (p  0.77). Random-
zation produced well-balanced treatment groups on all
ariables of prognostic importance (23), and direct adjust-
ent for distributional differences in age, race, and sex did
ot affect treatment group-specific AF/AFL prevalence
ates.
Older, male, and nonblack participants were more likely
o have AF/AFL at trial entry (Table 1). Octogenarians had
pproximately 5-fold greater odds of having AF/AFL than
hose in their 60s. After adjusting for the other baseline
haracteristics, AF/AFL prevalence increased by approxi-
ately 10% with each year after age 55 years (p  0.001)
Table 2); men were 1.72 times more likely than women to
ave AF/AFL (p  0.001, reciprocal of 0.581) (Table 2); and
onblacks were 2.09 times more likely than blacks (p 0.001).
aseline mean blood pressure for those with and without
F/AFL was similar (145.6/84.1 mm Hg vs. 146.3/84.0 mm
g, respectively), but AF/AFL was significantly more preva-
ent in those with a history of CHD, who were 1.34 times
ore likely than those without CHD to have AF/AFL (p 
.011) (Table 2). Those with ASCVD (of which CHD was a
omponent) were also more likely to have AF/AFL than those
ithout ASCVD (p  0.01) (Table 1). Similarly in adjusted
nd multivariable analyses, AF/AFL was significantly more
revalent in those not routinely taking aspirin (p  0.001), in
hose with body mass index (BMI) 30 kg/m2 (p  0.001),
nd with HDL 35 mg/dl (p  0.01).
AF/AFL was less prevalent in smokers and among
iabetics (each an ALLHAT eligibility criterion). This
ifference was largely due to the younger age distribution of
hese subgroups compared with their counterparts, and they
id not differ significantly in adjusted and multivariable
nalyses. There was no difference in the adjusted prevalence
atment Grouppants by Treatment Group
Univariable
Logistic Model
Multivariable
Logistic Model‡ Kaplan-Meier
Rate/1,000
ParticipantsOR p Value OR p Value
6 yrs
1.000 — 1.000 — 23.5
1.073 0.50 1.083 0.48 28.3
0.987 0.90 0.939 0.59 24.9
4 yrs
1.000 — 1.000 — 13.3
1.346 0.02 1.326 0.05 19.3
6 yrs
1.000 — 1.000 — 27.8
1.020 0.90 1.108 0.54 25.9
LHAT participants, in 2,669 (29.5%) of the 9,061 doxazosin participants, and in 1,773 (17.1%) of
ants who were missing a baseline electrocardiogram but whose first follow-up electrocardiogram
ratios’ equality with unity. †Age-sex-race adjusted rates; crude rates differed only for usual carey Trertici
†
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particip
of oddse logistic models.
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November 24, 2009:2023–31 Atrial Fibrillation in the ALLHAT Studyf AF/AFL when stratified by baseline estimated glomer-
lar filtration rate (eGFR) (25). Although the unadjusted
revalence was statistically greater for those with eGFR
60 ml/min per 1.73 m2, this was largely due to their older
ge (55% 70 years compared with 31% of those with
GFR 60 ml/min per 1.73 m2).
ncidence of AF/AFL. Follow-up ECGs were available
or 25,332 (76%) of 33,357 participants assigned to
hlorthalidone, lisinopril, or amlodipine. New AF/AFL de-
eloped in 537 (2.1%) of these participants (32 were AFL).
ables 3 and 4 present the number of new AF/AFL cases,
orresponding crude AF/AFL incidence per 1,000, and
Rs for developing AF/AFL. The multiple logistic analyses
resented in Table 4 were adjusted for distributional differ-
nces in age, race, sex, and pre-existing CHD.
There were no significant differences in development of
ew AF/AFL between the chlorthalidone group and the
isinopril or amlodipine groups during follow-up (Table 3),
or between the pravastatin and usual care groups. New-
nset AF/AFL was higher in those assigned to doxazosin
evelopment of AF/AFL During Follow-Up per 1,000 Participants,verall and by Major Subgroups (Doxazosin Participants Excluded)Table 4 Development of AF/AFL During Follow-Up per 1,000 PaOverall and by Major Subgroups (Doxazosin Participan
Subgroup
Sample
Size
New*
AF/AFL
All 25,332 537
Age 55–69 yrs 16,676 234
Age 70 yrs 8,656 303
Women 11,318 157
Men 14,014 380
Black 8,430 104
Nonblack 16,902 433
Diabetic 8,837 177
Nondiabetic 16,495 360
Smoker 5,401 80
Nonsmoker 19,931 457
CHD absent 18,862 329
CHD present 6,470 208
LVH absent 21,344 451
LVH present 1,083 45
ASCVD absent 13,443 207
ASCVD present 11,889 330
No aspirin 15,746 296
Aspirin use 9,586 241
Not treated for hypertension 2,382 35
Treated for hypertension 22,950 502
BMI 30 kg/m2 14,494 292
BMI 30 kg/m2 10,766 243
eGFR 60 ml/min per 1.73 m2 20,441 403
eGFR 60 ml/min per 1.73 m2 4,089 125
HDL 35 mg/dl 19,558 372
HDL 35 mg/dl 4,852 150
3-month K 3.5 mmol/l 19,781 439
3-month K 3.5 mmol/l 1,270 22
he occurrence of new AF/AFL could not be ascertained in 8,025 (24.1%) of the 33,357 ALLHAT, n
ases among the 1,735 participants who were missing a baseline electrocardiogram but whose fi
rror for the test of the ORs’ equality with unity. †Row-specific 5-variable models included age, race, sex
OR  odds ratio; K  serum potassium at 1 to 3 months post-randomization; other abbreviations asompared with chlorthalidone (OR: 1.35; p  0.02). The
ncidence of AF/AFL did not significantly differ by treat-
ent group within the demographic and clinical subgroups
xamined (data not shown).
There were differences in new AF/AFL occurrence be-
ween strata (Tables 4 and 5). Similar to the baseline
revalence findings, older subjects, men, nonblacks, and
hose with pre-existing CHD, high BMI, and low HDL
ad a higher incidence of AF/AFL. Unlike the prevalence
ata, LVH was associated with a 2-fold greater risk of
ncident AF/AFL (adjusted OR: 2.11; p  0.001). In
nivariate analysis, lower baseline eGFR was associated
ith a higher risk of incident AF/AFL (30.6 vs. 19.7 per
,000; p  0.001). However, as in the prevalence data, this
as likely due to the correlation of eGFR with age (0.308;
 0.001); in adjusted (multivariable) analysis (Table 4),
he OR did not differ significantly from 1.0. Similarly,
onsmokers tended to be older than smokers (p  0.001)
ue to the inclusion of smoking as an eligibility criterion,
nd nonsmoking was not a significant predictor of AF/AFL
pants,
cluded)
nts
000
Univariable
Logistic Model
Multivariable
Logistic Model†
OR p Value OR p Value
.2 — —
.0 1.000 1.000
.0 2.549 0.001 2.446 0.001
.9 1.000 1.000
.1 1.981 0.001 1.883 0.001
.3 1.000 1.000
.6 2.105 0.001 1.760 0.001
.0 1.000 1.000
.8 1.092 0.34 0.946 0.56
.8 1.000 1.000
.9 1.561 0.001 1.163 0.23
.4 1.000 1.000
.1 1.871 0.001 1.455 0.001
.1 1.000 1.000
.6 2.008 0.001 2.114 0.001
.4 1.000 1.000
.8 1.825 0.001 1.216 0.09
.8 1.000 1.000
.1 1.346 0.001 0.949 0.58
.7 1.000 1.000
.9 1.500 0.02 1.511 0.02
.1 1.000 1.000
.6 1.123 0.19 1.520 0.001
.7 1.000 1.000
.6 1.568 0.001 1.163 0.16
.0 1.000 1.000
.9 1.645 0.001 1.337 0.005
.1 1.000 1.000
.3 0.777 0.25 0.957 0.84
zosin participants. Ascertainment was similar for all 3 drug groups. *There were 14 AF and 2 AFL
w-up electrocardiogram was negative for AF/AFL. The p values represent the probability of type Irtici
ts Ex
Eve
per 1
21
14
35
13
27
12
25
20
21
14
22
17
32
21
41
15
27
18
25
14
21
20
22
19
30
19
30
22
17
ondoxa
rst follo, pre-existing CHD, and the tabulated variable.
in Table 1.
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Atrial Fibrillation in the ALLHAT Study November 24, 2009:2023–31n the multiple logistic analysis (Table 4). Unlike the
revalence data, participants treated for hypertension before
ntering the trial (90% of ALLHAT participants) were 50%
ore likely to develop new AF/AFL. However, prior BP
edication use was not significant after adjusting for other
rognostic factors (Table 5).
Table 5 presents results of multiple logistic regression
nalysis of new-onset AF/AFL among ALLHAT partici-
ants assigned to chlorthalidone, amlodipine, and lisinopril.
he OR estimates are presented along with the correspond-
ng 95% CIs and a p value for the statistical test (z-test) that
he OR differs from 1.0.
rognosis of AF/AFL. Kaplan-Meier cumulative event
urves for major clinical outcomes according to baseline
F/AFL status are shown in Figure 1. The hazard ratio
HR) for all-cause mortality was 2.82 (95% CI: 2.36 to 3.37;
 0.001), with curve divergence beginning early and
ontinuing to trial end (age-sex-race adjusted HR: 2.01;
5% CI: 1.68 to 2.41). For CHD (HR: 1.64; 95% CI: 1.22
o 2.21; p  0.01), curve separation is not dramatic until
ear 3, but continues to widen through year 6 (adjusted HR:
.24; 95% CI: 0.93 to 1.67). The most dramatic outcome
elated to AF/AFL is the much higher event rate for stroke
HR: 3.63; 95% CI: 2.72 to 4.86; p  0.001); again, curve
eparation begins early and continues until trial termination
adjusted HR: 2.84; 95% CI: 2.12 to 3.80). There was also
striking difference in heart failure event rates between
roups (HR: 3.17; 95% CI: 2.38 to 4.25; p  0.001;
djusted HR: 2.35; 95% CI: 1.76 to 3.15).
Figure 2 shows cumulative all-cause mortality in partic-
pants with AF/AFL at trial entry or occurring during
ollow-up (n 821) compared with those without AF/AFL
n  27,247). Participants who died before a follow-up
stimated ORs and Corresponding SEs and 95% CIsor Incidence of AF/AFL Am g NondoxazosinLLHAT Participants
Table 5
E timated ORs and C rre ponding SEs and 95% CIs
for Incidence of AF/AFL Among Nondoxazosin
ALLHAT Participants
Baseline Characteristic* OR SE (OR) 95% CI p Value
Amlodipine/chlorthalidone 1.082 0.120 0.870–1.346 0.48
Lisinopril/chlorthalidone 0.939 0.110 0.747–1.181 0.59
Age, yrs 1.068 0.007 1.054–1.082 0.001
Sex, female/male 0.536 0.058 0.434–0.663 0.001
Race, black/nonblack 0.583 0.072 0.458–0.746 0.001
Diabetic 1.030 0.105 0.843–1.257 0.77
Smoker 0.961 0.129 0.739–1.250 0.77
With CHD 1.499 0.153 1.227–1.832 0.001
With LVH 2.182 0.366 1.571–3.031 0.001
Treated for hypertension 1.237 0.222 0.870–1.757 0.24
Aspirin user 0.956 0.095 0.786–1.162 0.65
BMI 30 kg/m2 1.580 0.154 1.305–1.913 0.001
eGFR 60 ml/min per 1.73 m2 1.116 0.127 0.892–1.395 0.34
HDL 35 mg/dl 1.305 0.141 1.056–1.612 0.01
3-month K 3.5 mmol/l 0.973 0.225 0.618–1.532 0.90
stimates are based on a multivariable logistic regression model (n  21,739). *ASCVD was excluded
ecause CHD is a component.
Abbreviations as in Tables 1, 2, and 4.CG could be obtained were classified as AF/AFL absent. dhere was a nearly 2.5-fold increase in the risk of death
mong those with AF/AFL compared with those without
HR: 2.42; 95% CI: 2.11 to 2.77; p  0.001). The
ge-sex-race adjusted HR was 1.86 (95% CI: 1.63 to 2.14;
 0.001).
iscussion
he prevalence of AF/AFL in ALLHAT baseline ECGs
as 10.8 per 1,000. As expected from previous studies, the
revalence increased with age and was higher in men and
bese individuals. However, in this hypertensive cohort,
either diabetes nor cigarette smoking was associated with
ncreased risk of AF/AFL. The lower prevalence of AF/
FL in black versus nonblack ALLHAT participants is
onsistent with data from the ATRIA study and national
ortality data (8,9). A study of racial differences in AF
revalence among males followed in the Department of
eterans Affairs health system yielded similar findings,
lthough ECG confirmation of AF was not available
26,27). The EPOCH (Epidemiology, Practice, Outcomes,
nd Costs of Heart Failure) study further documents a
ignificantly lower (49%) adjusted OR for AF/AFL among
frican-American heart failure patients compared with
aucasians (28).
Baseline prevalence of AF/AFL in the 4 ALLHAT
andomized treatment groups was not associated with dif-
erential significance of the baseline risk descriptors. During
ollow-up, the incidence of new AF/AFL in chlorthalidone,
mlodipine, and lisinopril participants (21.2 per 1,000
verall) did not differ significantly among treatment groups.
actors favoring development of new-onset AF/AFL were
imilar to those associated with baseline prevalence, includ-
ng older age, male sex, nonblack race, CHD, arterioscle-
otic CVD, LVH, BMI 30 kg/m2, and HDL 35 mg/dl.
he observed higher unadjusted incidence of AF/AFL in
articipants with worse renal function was largely explained
y adjusting for age. Hypokalemia did not emerge as a
rognostic factor in the incidence of AF/AFL.
AF/AFL prevalence and incidence during follow-up were
trongly related to participant outcomes in the ALLHAT
rial. AF/AFL at baseline was associated with an almost
-fold increase in all-cause mortality during follow-up (HR:
.82; p  0.001), a 3.5-fold increase in the occurrence of
troke, a 3-fold increase in new-onset heart failure, and a
ubstantial increase in the occurrence of fatal CHD or
onfatal myocardial infarction (HR: 1.64; p  0.01).
otably, the 6-year incidence rates for fatal and nonfatal
troke in the ALLHAT trial were higher for the black
opulation compared with nonblacks (6.6% vs. 5.5%) de-
pite substantially less AF/AFL, suggesting that factors
ther than AF/AFL are responsible for the high stroke rates
n this group (29).
Despite suggestions in the literature of a favorable effect
f ACE inhibitors on the likelihood of new-onset AF, no
ifferences in the incidence of AF/AFL were observed
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November 24, 2009:2023–31 Atrial Fibrillation in the ALLHAT Studyetween the treatment groups in this study (15–17). This
ay reflect the limited prospective data in hypertensive
atients upon which the earlier conclusions were based, or
he lesser blood pressure reduction in the lisinopril group in
he ALLHAT trial, or possibly low statistical power to
etect such an effect.
Whether blockade of the renin-angiotensin system by
n angiotensin II receptor blocker (ARB) would have been
ore effective than lisinopril could not be determined in the
LLHAT trial. A review of ARB effectiveness in hyper-
ension and heart failure trials summarizes possible mecha-
isms but does not conclude that ARBs are better than
CE inhibitors for AF prevention (30). LIFE (Losartan
ntervention for End Point Reduction in Hypertension) and
ALUE (Valsartan Antihypertensive Long-Term Use
valuation) hypertension trials reported significant de-
reases in AF rates for losartan compared with atenolol and
alsartan compared with amlodipine, respectively. In heart
ailure trials, candesartan reduced new-onset AF compared
ith placebo (CHARM [Candesartan in Heart failure:
ssessment of Reduction in Mortality and morbidity]),
Figure 1 Kaplan-Meier Event Curves for All-Cause Mortality, CH
Kaplan-Meier event curves for all-cause mortality, coronary heart disease (CHD), s
pants with atrial fibrillation (AF) or atrial flutter (AFL) at trial entry (n  334) compa
dial infarction; RR  relative risk (hazard ratio).hereas valsartan compared with placebo was ineffective in fhe participants in Val-HeFT (Valsartan Heart Failure
rial), 92% of whom were being concurrently treated with
n ACE inhibitor (17,31–33). In the LIFE trial, the risk
f stroke was significantly reduced in the losartan group
17). In the ALLHAT trial, there was a higher risk of
troke in black participants assigned to lisinopril, whereas
he risk of new-onset AF/AFL was lower in black versus
onblack participants.
There has been considerable interest in whether the inci-
ence or recurrence of AF is lessened by treatment with statins.
ost published studies have been post-hoc observational
nalyses or secondary analyses from trials with other end points
34,35). The presumed mechanism of such an effect, if present,
s prevention or reversal of atrial fibrosis, which has been
ncreased in animal models and patients with atrial fibrillation.
owever, as has proven to be the case with renin-angiotensin-
ldosterone system inhibitors, there has been no clear evidence
f a preventative effect of statins in large, well-designed
andomized clinical trials of statins. The findings from
LLHAT add importantly to this literature, in that this is
ne of the largest cohorts of patients with multiple risk
troke, and HF
and heart failure (HF) among chlorthalidone, amiodipine, and lisinopril partici-
th those without AF/AFL (n  30,370). CI  confidence interval; MI  myocar-D, S
troke,
red wiactors for developing AF (chronic hypertension, older age,
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Atrial Fibrillation in the ALLHAT Study November 24, 2009:2023–31nd coronary risk factors) prospectively randomized to a
tatin with long-term follow-up. The finding that pravasta-
in treatment was not associated with a lower incidence of
F raises doubt regarding the validity of this hypothesis and
ertainly mandates further rigorous study before these
gents can be recommended for prevention of AF.
New-onset of AF/AFL during follow-up was shown to
arry a mortality risk at least as high as that among
articipants with pre-existing AF/AFL. The 6-year mortal-
ty rate among those with pre-existing or new-onset AF/
FL was 42% compared with 40% among those with
re-existing AF/AFL. However, the mean time to new
F/AFL was 3.6 years, allowing significantly less additional
ears of follow-up for mortality among this group as
ompared with those with AF/AFL at baseline. Further
nalyses are needed to explore differences between mortality
isk associated with pre-existing and new-onset AF/AFL.
The findings reported here are of great significance
ecause of the marked effect of AF/AFL on the outcomes of
atients despite aggressive treatment in the ALLHAT trial
nd the associated interplay of unalterable risk factors such
s age, race, and sex. Thus, aggressive management of
F/AFL according to existing guidelines, including use of
nticoagulation, should be integrated into the management
f hypertension. Awareness of the increased risk of these
atients may warrant closer follow-up and more aggressive
anagement of other risk factors. Similarly, the higher risk
f AF/AFL in participants with CHD, LVH, and BMI
30 kg/m2 suggests that prevention and treatment of risk
Figure 2 Kaplan-Meier Cumulative Event
Curves for All-Cause Mortality
Kaplan-Meier cumulative event curves for all-cause mortality in chlorthalidone,
amiodipine, and lisinopril participants with AF/AFL at trial entry or occurring
during follow-up (n  821) compared with mortality in those without AF/AFL
(n  27,247). In this time-dependent analysis, participants without AF/AFL at
baseline remained in the AF/AFL absent risk group until new-onset AF/AFL was
ascertained, at which time they were reclassified as AF/AFL present. Partici-
pants who died before a follow-up electrocardiogram could be obtained were
classified as AF/AFL absent. Abbreviations as in Figure 1.actors, including obesity, might prevent AF.
etudy strengths and limitations. Evaluation of AF/AFL
as an ancillary study to ALLHAT, pre-specified early in
he trial, but not included in the protocol. Data are not
vailable to assess to what extent the management of
F/AFL in ALLHAT participants met current recommen-
ations or whether adjustments in management or earlier
etection might have affected results. As with prior longi-
udinal studies documenting AF risks, the use of anticoag-
lation agents was not closely monitored, and adjustment
or their use was not possible. AF/AFL incidence could not
e ascertained in 8,000 ALLHAT participants leaving the
xact magnitude of the AF/AFL incidence uncertain, al-
hough missing observations were similar across treatment
roups. With an overall rate of 2.1%, large effect sizes would
ave been necessary to detect something with adequate
ower, and the ALLHAT trial was not designed for this
urpose. Future longitudinal studies involving similar pa-
ient populations should consider the potential for outcome
esults to be altered by the presence of AF at baseline or its
ccurrence during follow-up. The large number of black
articipants in the ALLHAT trial was a major asset in
alidating the lower prevalence and incidence of AF in
lacks. Failure to find differential AF/AFL occurrence rates
y treatment assignment in this large, randomized trial
aises questions regarding whether previous studies suggest-
ng lower new-onset AF/AFL rates with ACE inhibitors or
RBs are generalizable.
onclusions
LLHAT, the largest prospective, randomized hyperten-
ion treatment trial, afforded the opportunity to examine the
nfluence of AF at baseline and its appearance during
ollow-up on outcomes in the trial. Several striking findings
ere observed, including the lower prevalence and incidence
f AF in black participants, the lack of difference by
reatment group (except for doxazosin) on the incidence of
ew-onset AF, and the marked increase in risk for fatal and
ajor nonfatal cardiovascular outcomes. These results un-
erscore the importance of prevention, early detection, and
ppropriate management of AF in hypertensive patients, in
ddition to aggressive BP control. Further studies are
ndicated to determine whether the application of specific
F management guidelines might alter outcome in specific
opulations.
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